GTx, Inc. (GTXI) Reports Q4 Loss of $0.44/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
GTx Provides Corporate Update and Reports Fourth Quarter and Year-End 2016 Financial Results
March 15, 2017 7:00 AM EDT-- Enobosarm demonstrated clinical benefit and met the primary efficacy endpoint for the 9 mg dose cohort in GTxs ongoing ER+/AR+ Phase 2 breast cancer trial --
-- Company expects to report preliminary results from its Phase 2 clinical trial of enobosarm to treat Stress Urinary Incontinence (SUI) in the third quarter of 2017 --
-- Company expects to begin an initial clinical study of a Selective Androgen Receptor Degrader (SARD) in men with castration-resistant prostate cancer in the second half of 2017 --
MEMPHIS, Tenn.--(BUSINESS WIRE)--... More
